Publications by authors named "He-Bing Zhou"

Article Synopsis
  • This study looked at how well two treatments (IRd and IDd) work for older, frail patients with a type of cancer called multiple myeloma.
  • 120 patients aged 65 and older participated and received different combinations of medicines to see which worked better and was safer.
  • Results showed that both treatments helped many patients, but there were different rates of side effects and how long patients stayed healthy after treatment.
View Article and Find Full Text PDF

Objective: To investigate the biological function of miR-203a-5p and the underlying mechanism in multiple myeloma (MM).

Methods: Three miRNA expression profiles (GSE16558, GSE24371 and GSE17498) were downloaded from the GEO database. The three miRNA expression profiles contained 131 MM samples and 17 normal plasmacyte samples.

View Article and Find Full Text PDF
Article Synopsis
  • Intracranial hemorrhage (ICH) is a serious and sometimes fatal condition in adults with immune thrombocytopenia (ITP), with a mortality rate of 33.80% based on a study of 142 cases in China from 2005 to 2020.
  • The study identified several risk factors for 30-day mortality, including low platelet counts, the type of hemorrhage, and the level of consciousness at admission, and developed a prognostic model to predict outcomes.
  • The model was validated internally and externally, showing strong predictive performance, and an application was created to help healthcare providers estimate the risk of mortality in ITP patients experiencing ICH.
View Article and Find Full Text PDF

The study aimed to compare the efficacy and safety of all-trans retinoic acid (ATRA) plus low-dose rituximab (LD-RTX) with LD-RTX monotherapy in corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) patients. Recruited patients were randomized at a ratio of 2:1 into 2 groups: 112 patients received LD-RTX plus ATRA, and 56 patients received LD-RTX monotherapy. Overall response (OR), defined as achieving a platelet count of ≥30 × 109/L confirmed on ≥2 separate occasions (≥7 days apart), at least a doubling of the baseline platelet count without any other ITP-specific treatment, and the absence of bleeding within 1 year after enrollment, was observed in more patients in the LD-RTX plus ATRA group (80%) than in the LD-RTX monotherapy group (59%) (between-group difference, 0.

View Article and Find Full Text PDF

Intracranial hemorrhage (ICH) is a devastating complication of immune thrombocytopenia (ITP). However, information on ICH in ITP patients under the age of 60 years is limited, and no predictive tools are available in clinical practice. A total of 93 adult patients with ITP who developed ICH before 60 years of age were retrospectively identified from 2005 to 2019 by 27 centers in China.

View Article and Find Full Text PDF

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening haematological emergency. Although therapeutic plasma exchange together with corticosteroids achieve successful outcomes, a considerable number of patients remain refractory to this treatment and require early initiation of intensive therapy. However, a method for the early identification of refractory iTTP is not available.

View Article and Find Full Text PDF

To establish a nomogram for predicting the overall survival (OS) of patients with newly diagnosed multiple myeloma (MM), 304 patients with newly diagnosed MM were recruited between June 1, 2010, and June 30, 2015, from the Beijing Chaoyang Hospital, Capital Medical University, and randomly divided into training (n=214) and validation (n=90) cohorts. The Kaplan-Meier method and the Cox proportional hazards regression model were used to evaluate the prognostic effects of multiple clinical and laboratory parameters on survival. Significant prognostic factors were combined to build a nomogram.

View Article and Find Full Text PDF
Article Synopsis
  • Recent studies indicate that the lymphocyte-to-monocyte ratio (LMR) at diagnosis can predict survival in tumor patients, including those with multiple myeloma (MM).
  • In a study of 285 MM patients undergoing treatment with novel drugs, an LMR ≤ 4.2 was associated with significantly poorer overall survival (OS) and progression-free survival (PFS) compared to those with LMR > 4.2.
  • LMR < 4.2 was identified as an independent prognostic factor for worse OS and PFS, highlighting its potential as a simple index for assessing systemic immunity and predicting clinical outcomes in MM patients.
View Article and Find Full Text PDF

The aim of this study was to establish nomograms, based on significant clinicopathologic parameters, for predicting the overall survival (OS) and the cancer-specific survival (CSS) of patients with classical Hodgkin lymphoma (CHL). The data of 43,330 CHL patients, diagnosed between 1983 and 2014, were obtainedfrom the database of the Surveillance, Epidemiology, and End Results (SEER) program. These patients were randomly divided into training (n = 30,339) and validation (n = 12,991) cohorts.

View Article and Find Full Text PDF

Objective: This study was aimed to investigate the roles of PDCD5 (programmed cell death 5) in pathogenesis of acute myeloid leukemia (AML) and the relevance of PDCD5 with the clinical characteristics and prognosis of patients by testing the PDCD5 expression in adult AML patients.

Methods: The mRNA and intracellular protein levels of PDCD5 from 36 newly diagnosed AML patients were analyzed by real-time fluorescence quantitative polymerase chain reaction (RQ-PCR) and flow cytometry (FCM), respectively. The correlation of mRNA levels and intracellular protein levels of PDCD5 with the clinical characteristics and survival time of patients were analyzed.

View Article and Find Full Text PDF

This study was aimed to investigate the role of B-cell lymphoma 2 (BCL-2) in pathogenesis of hyperleukocytic acute myeloid leukemia (AML). The levels of intracellular BCL-2 in 48 AML patients were detected by flow cytometry (FCM). Serum levels of BCL-2 in 40 AML patients were measured by enzyme-linked immunosorbent assay (ELISA).

View Article and Find Full Text PDF